In which country is tibolone approved for use regarding osteoporosis?

Tibolone is a synthetic steroid that is used in the management of menopause-related symptoms and prevention of osteoporosis. It has been approved in various countries for different uses. In this context, it is essential to note that tibolone has been particularly recognized for its effectiveness in preventing osteoporosis in postmenopausal women.

In Mexico, tibolone has been formally sanctioned for use in osteoporosis treatment, reflecting the country's acceptance of this medication's benefits for managing menopausal symptoms and maintaining bone health. This approval allows healthcare providers in Mexico to utilize tibolone as part of treatment regimens for women at risk of osteoporosis due to menopause.

In contrast, other regions such as the United States and Canada have not granted approval for tibolone specifically for osteoporosis treatment, often relying on alternative therapies. Australia, while having tibolone available for hormone replacement therapy, does not approve it for osteoporosis management. The differences in approval status across these countries highlight the varied regulatory approaches to menopause-related therapies and the specific clinical evidence that supports a drug's use in different contexts.